Core Viewpoint - The Tianhong Nonferrous Metals ETF (159157) has shown strong performance, leading the market in trading volume and net inflows, indicating a growing interest in the nonferrous metals sector driven by various market dynamics [1][2][3]. Group 1: ETF Performance - As of February 24, the Tianhong Nonferrous Metals ETF reached a record size of 2.159 billion yuan and a total of 2.173 billion shares, marking new highs since its inception [2]. - The ETF recorded a turnover of 9.37% with a trading volume of 208 million yuan, ranking first among similar products in the Shenzhen market [1]. - Over the past week, the ETF has seen continuous net inflows, with a peak single-day inflow of 269 million yuan, totaling 1.067 billion yuan in net inflows [3]. Group 2: Market Trends - The CSI Industrial Nonferrous Metals Theme Index, which the ETF tracks, surged by 5.40%, with notable increases in constituent stocks such as Chihong Zn & Ge (up 10.01%), Tin Industry Co. (up 10.00%), and Northern Rare Earth (up 9.99%) [1]. - The ETF focuses on key metals like copper, aluminum, and rare earths, covering 30 leading companies in the industry, thus providing a strategic investment opportunity amid AI-driven, strategic resource, and cyclical upturn trends [4]. Group 3: Relevant Events - The Trump administration plans to utilize AI to set reference prices for critical minerals, including germanium, gallium, antimony, and tungsten, aiming to establish a global metal trading group [5]. - This initiative is intended to attract allies and protect domestic mining companies through transparent pricing, although the effectiveness of AI pricing and international cooperation remains under scrutiny [5]. Group 4: Institutional Insights - Citic Securities has noted significant fluctuations in gold prices, attributing them to market concerns over the Federal Reserve's independence and geopolitical uncertainties, which may affect the broader precious and nonferrous metals market outlook [6].

Core Insights - The Shanghai Gold ETF (159830) has seen a turnover of 5.94% and a transaction volume of 221 million yuan as of February 13, 2026, with a net inflow of 9.92 million yuan [1] - International gold prices have risen nearly 4% during the holiday period, surpassing the 5200 USD mark, driven by increased market risk aversion due to new tariff policies and economic data from the U.S. [2] - UBS maintains a positive outlook on gold, projecting a target price of 6200 USD per ounce in the coming months, citing geopolitical risks and continued central bank purchases as key drivers [2] Product Highlights - The Shanghai Gold ETF (159830) has a total management and custody fee of 0.30%, which is lower than the average fee of 0.60% for most gold ETFs [1] - The ETF has reached a new high in shares since its inception, indicating strong investor interest and confidence [1] Related Products - The Shanghai Gold ETF (159830) is linked to off-market funds, including Connect Fund A (014661) and Connect Fund C (014662) [1] - Other ETFs mentioned include various sector-focused funds such as the Technology ETF, Biopharmaceutical ETF, and Aerospace ETF, indicating a diverse range of investment opportunities in the market [3][4]

Core Insights - The ChiNext ETF Tianhong (159977) has seen significant trading activity, with a transaction volume of 117 million yuan and a strong increase of 3.06% in the tracked ChiNext Index (399006) [1] - The ChiNext ETF Tianhong (159977) has experienced a substantial growth of 11.76 million shares over the past six months, with a total net inflow of 44.08 million yuan in the last four days [2] Product Highlights - The ChiNext ETF Tianhong (159977) offers several advantages: it bundles a variety of ChiNext stocks, has a daily price fluctuation limit of ±20%, requires no asset or investment duration for account opening, and allows for convenient trading like stocks [3] Industry Events - The Shanghai government highlighted its strengths in the artificial intelligence sector, including collaborative industrial clusters, large market scenarios, talent supply, and a complete financial system. Shanghai accounts for nearly 10% of the national computing power and has launched various initiatives to support AI development [4] Institutional Views - Guotai Junan Securities noted that the market remains in a high volatility state before the Spring Festival, suggesting that the next wave of market activity will likely be based on logic rather than sentiment. They anticipate a potential resurgence of technology growth stocks after the Spring Festival [5]

Group 1 - The major indices collectively rose on February 3, with the National Bio-Medical Index (399441) increasing by 1.15%. Notable stocks included Zhaoyan New Drug and Aimeike, both rising over 4%, while Tigermed and Huaxi Biological increased by over 3%, and Kailaiying rose nearly 3% [1] - The Bio-Medical ETF (159859) had a trading volume exceeding 65 million yuan, ranking first among its peers. The net inflow for this ETF on the previous trading day (February 2) was 67.29 million yuan, and it has seen continuous net inflows over the past 10 days, accumulating over 440 million yuan [1] - The latest circulating share of the Bio-Medical ETF is 9.569 billion shares, with a total market size of 3.674 billion yuan, making it the largest in its category [1] Group 2 - The Shanghai Municipal Government's work report emphasized the need to deepen the construction of an international economic center, focusing on modern industrial systems and supporting sectors such as bio-medicine, integrated circuits, and artificial intelligence [2] - According to Zhongtai Securities, the pharmaceutical market opportunities are expected to revolve around thematic opportunities, with potential performances in brain-computer interfaces, AI healthcare, and small nucleic acids. There is also a strategic emphasis on the raw material drug sector, which is at a bottom range and may see a mid-term positive cycle due to rising chemical prices and new business additions [2]

Group 1: ETF Performance - As of February 2, 2026, the Medical Equipment ETF (159873) had a turnover of 5.82% with a transaction volume of 14.6087 million yuan, while the tracked index, the CSI All Share Healthcare Equipment and Services Index (H30178), fell by 1.44% [1] - The Medical Equipment ETF (159873) saw a net subscription of 11 million shares during the trading session [2] - The Biopharmaceutical ETF (159859) had a turnover of 3.87% with a transaction volume of 142 million yuan, and the corresponding index, the National Biopharmaceutical Index (399441), decreased by 2.18% [2] Group 2: Fund Flows - The Medical Equipment ETF (159873) experienced a net inflow of 4.2585 million yuan, with a total of 22.8076 million yuan net inflow over the last five trading days [2] - The Biopharmaceutical ETF (159859) achieved a new high in scale at 3.705 billion yuan and a new high in shares at 9.396 billion shares as of January 30 [3] - The Biopharmaceutical ETF (159859) has seen continuous net inflows over the past ten days, totaling 425 million yuan [3] Group 3: Sector Insights - The Medical Equipment ETF (159873) has a high content of brain-computer interface technology, accounting for over 17%, indicating strong technological attributes [3] - The overall industry landscape for medical devices is improving, with leading companies showing performance recovery in Q3, suggesting potential for future capital inflows [6] - The innovative drug sector is expected to see a recovery phase, with a focus on domestic innovation and increased global participation, indicating a positive outlook for investment opportunities [7]

Group 1 - The three major indices collectively rose, while the National Securities Biopharmaceutical Index (399441) fell by 0.84%. Among its constituent stocks, Kanglong Chemical rose over 1%, Hualan Biological increased by 0.59%, Tigermed gained 0.52%, and Jianfan Biological was up by 0.5% [1] - The Biopharmaceutical ETF (159859) had a trading volume of 100 million yuan yesterday, ranking first among similar products. According to Wind data, the ETF saw a net subscription of over 130 million shares yesterday [1] - As of January 21, the Biopharmaceutical ETF experienced a net inflow of 23.95 million yuan, marking three consecutive trading days of net inflows, with a cumulative net inflow of 116 million yuan [1] Group 2 - The Biopharmaceutical ETF closely tracks the Biopharmaceutical Index, which is based on A-share listed companies in the biopharmaceutical industry, selecting the top 30 stocks based on market capitalization and liquidity [1] - Nine departments, including the Ministry of Commerce and the National Development and Reform Commission, jointly issued opinions to promote high-quality development in the pharmaceutical retail industry, proposing 18 specific measures [1] - According to Pacific Securities, the biopharmaceutical industry will enter a critical phase of innovation realization and global layout by 2026, supported by the synergy of industry, policy, and capital [2]

Group 1 - The CRO and innovative drug sectors are experiencing strong gains, with stocks like Rongchang Biopharma A-shares and H-shares, WuXi AppTec, and Sanofi rising by 17%, 9%, 7.9%, and 7.2% respectively, leading to a 3.5% increase in the Tianhong Innovative Drug ETF [1] - The Tianhong Innovative Drug ETF (517380) is the only ETF tracking the Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50 Index, focusing on 50 actively traded innovative drug and CXO companies with high R&D investment [1] - The ETF has seen a net inflow of 207 million yuan over the past five days, indicating strong investor interest [1] Group 2 - The 44th JPMorgan Global Healthcare Conference is set to take place, with over 20 domestic innovative drug companies confirmed to participate, including WuXi AppTec and several others [1] - WuXi AppTec is projected to achieve a profit of 19.151 billion yuan in 2025, representing a year-on-year increase of 103%, with Q4 net profit expected to reach 7.075 billion yuan, a quarter-on-quarter increase of 101% [1] - The sixth batch of national centralized procurement for high-value medical consumables is about to open for bidding, including 12 types of medical consumables [2] Group 3 - The medical device ETF (159873) has a significant focus on brain-machine interfaces, accounting for over 19% of its composition, indicating strong technological attributes [2] - The ETF's components include a high proportion of stocks from the Sci-Tech Innovation Board and the Growth Enterprise Market, nearly 80%, suggesting a robust growth potential [2] - The industry outlook for 2026 remains positive, with a focus on innovation, international expansion, and recovery in challenging markets, particularly in the CXO and upstream supply chain sectors [2]

Group 1 - The CRO and innovative drug sectors are experiencing strong gains, with Rongchang Biopharma A-shares rising by 17%, H-shares by 9%, WuXi AppTec by 7.9%, and 3SBio by 7.2%, leading to a 3.5% increase in the Tianhong Innovative Drug ETF, outperforming the Hong Kong Stock Connect innovative drug index (2.25%) and the Hong Kong innovative drug index (0.18%) [1] - The Tianhong Innovative Drug ETF (517380) is the only ETF tracking the Hang Seng-Hushen-Hong Kong innovative drug selected 50 index, comprising 50 actively traded innovative drug and CXO companies with high R&D investment [1] - The ETF has seen a net inflow of 207 million yuan over the past five days, indicating strong investor interest [1] Group 2 - The 44th JPMorgan Global Healthcare Conference is set to take place on January 12, featuring over 20 domestic innovative drug companies, including WuXi AppTec and several others [2] - WuXi AppTec is projected to achieve a pre-tax profit of 19.151 billion yuan in 2025, representing a year-on-year increase of 103%, with Q4 net profit expected to reach 7.075 billion yuan, a quarter-on-quarter increase of 101% [2] - The sixth batch of national centralized procurement for high-value medical consumables is about to open for bidding, including 12 types of medical consumables [2] Group 3 - Guotai Junan Securities is optimistic about the pharmaceutical industry in 2026, focusing on innovation, overseas expansion, and recovery trends, with an emphasis on innovative drugs and supply chains as foundational investments [2] - The medical device ETF (159873) has a significant focus on brain-computer interfaces, accounting for over 19%, and is expected to benefit from domestic innovation, accelerated exports, and new technologies [2] - The biopharmaceutical ETF (159859) is recommended for its higher concentration and focus on 30 industry leaders, offering greater sharpness and elasticity in the market [2]

Core Insights - The innovative drug ETF Tianhong (517380) has seen significant trading activity, with a transaction volume of 7.76 million yuan as of November 7, 2025, and a record high of 1.74 billion shares outstanding [2] - The biopharmaceutical ETF (159859) has also experienced strong performance, with a recent increase of 20.23% over the past six months, ranking first among comparable funds [3] Fund Performance - The innovative drug ETF Tianhong (517380) has achieved a net inflow of 78.80 million yuan over the past six days, with a peak single-day inflow of 22.82 million yuan [3] - The biopharmaceutical ETF (159859) has recorded a total net inflow of 199 million yuan in the same period, with a maximum single-day inflow of 61.78 million yuan [3] Policy Developments - Chongqing has introduced new policies to support the development of innovative drugs, offering rewards of up to 10 million yuan for the cultivation of industrial clusters [4] - The policy aims to approve 1 to 3 innovative drugs annually by 2027, with a target of reaching a total of 10 innovative drugs [4] Industry Outlook - The pharmaceutical sector showed signs of recovery in Q3 2025, with revenue and net profit growth turning positive, particularly in the medical research outsourcing sector, which saw revenue and net profit growth rates of 10.9% and 47.9%, respectively [5] - The investment sentiment in the innovation-related pharmaceutical chain, including chemical drugs and biopharmaceuticals, is expected to stabilize due to improving performance and potential policy benefits [5]

Core Viewpoint - The biopharmaceutical ETF (159859) has seen significant trading activity and net inflows, indicating strong investor interest in the sector, particularly in innovative drug companies [3][4][5]. Group 1: ETF Performance - As of November 4, the biopharmaceutical ETF (159859) has increased by 22.58% over the past six months, ranking first among comparable funds [4]. - The ETF has achieved a recent high in total shares, reaching 7.674 billion shares [4]. - In the last week, the ETF experienced an average daily trading volume of 139 million yuan, also ranking first among comparable funds [4]. Group 2: Fund Inflows - The biopharmaceutical ETF (159859) has seen a net inflow of 122 million yuan over the past four days [4]. - The innovative drug ETF Tianhong (517380) has also experienced net inflows totaling 61.32 million yuan in the same period [5]. Group 3: Market Trends - The recent negotiations for the national basic medical insurance drug catalog have concluded successfully, with 120 companies participating, indicating a stable pricing mechanism for drugs [6]. - The average price reduction for drugs in recent years has stabilized, with the expected burden reduction for patients exceeding 50 billion yuan in 2025 [6]. - Analysts from Zhongtai Securities suggest that despite a weak performance in the pharmaceutical sector in October, the fundamentals remain strong, and innovative drugs are expected to rebound [6].